Second-line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Antonin Levy
No relevant relationships to disclose
Jean Menard
No relevant relationships to disclose
Laurence Albiges
No relevant relationships to disclose
Mario Di Palma
No relevant relationships to disclose
Karim Fizazi
Consultant or Advisory Role - Bayer; Novartis; Roche
Bernard J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer